S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33

HUTCHMED (NASDAQ:HCM) Downgraded by The Goldman Sachs Group to "Neutral"

Last updated on Wednesday, September 22, 2021 | 2021 MarketBeat

HUTCHMED (NASDAQ:HCM) was downgraded by analysts at The Goldman Sachs Group from a "buy" rating to a "neutral" rating in a note issued to investors on Wednesday, The Fly reports.

HCM has been the topic of several other research reports. Zacks Investment Research raised HUTCHMED from a "sell" rating to a "hold" rating in a research note on Tuesday, September 14th. Cantor Fitzgerald upped their price target on HUTCHMED from $40.00 to $45.00 and gave the stock an "overweight" rating in a report on Tuesday, July 13th. Finally, Jefferies Financial Group assumed coverage on HUTCHMED in a report on Tuesday, August 3rd. They set a "buy" rating and a $52.00 price target on the stock. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $44.25.

HCM opened at $38.18 on Wednesday. The stock's 50-day moving average price is $40.02 and its 200 day moving average price is $33.29. HUTCHMED has a 12-month low of $23.67 and a 12-month high of $43.94. The company has a current ratio of 4.41, a quick ratio of 4.30 and a debt-to-equity ratio of 0.05. The firm has a market cap of $6.60 billion, a price-to-earnings ratio of -42.42 and a beta of 1.08.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quadrant Capital Group LLC increased its holdings in shares of HUTCHMED by 227.3% in the 2nd quarter. Quadrant Capital Group LLC now owns 635 shares of the company's stock valued at $25,000 after acquiring an additional 441 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of HUTCHMED by 36.0% in the 2nd quarter. PNC Financial Services Group Inc. now owns 2,622 shares of the company's stock valued at $104,000 after acquiring an additional 694 shares during the last quarter. Lazard Asset Management LLC purchased a new position in shares of HUTCHMED in the 2nd quarter valued at about $199,000. Ensign Peak Advisors Inc increased its holdings in shares of HUTCHMED by 300.0% in the 1st quarter. Ensign Peak Advisors Inc now owns 5,200 shares of the company's stock valued at $147,000 after acquiring an additional 3,900 shares during the last quarter. Finally, Nomura Asset Management Co. Ltd. purchased a new position in shares of HUTCHMED in the 2nd quarter valued at about $204,000. Institutional investors and hedge funds own 26.60% of the company's stock.

HUTCHMED Company Profile

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products.

Featured Article: Investing strategies using the yield curve

The Fly logo

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in HUTCHMED right now?

Before you consider HUTCHMED, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.

While HUTCHMED currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 


Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.